Multiple Myeloma
Advertisement
In the IKEMA trial, researchers compared carfilzomib and dexamethasone plus isatuximab against carfilzomib and ...
In Docwire News’ roundtable series discussing research presented at ASH 2021, moderator Dr. Saad Usmani is joined by ...
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, looks into the future of ...
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the safety and ...
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, describes the new ...
The bispecific antibody teclistamab displayed a manageable safety profile at the recommended phase II dose and continued ...
Whole–body diffusion–weighted imaging (WB-DWI) is used for evaluating patients with newly diagnosed multiple myeloma ...
In a study, published in Hematological Oncology, researchers examined the demographic characteristics, pathological ...
Bortezomib is a proven treatment for patients with multiple myeloma (MM), however, some patients achieve suboptimal ...
According to Szabolcs Kiss, MD, and colleagues, the most optimal first–line treatment regimen for patients with newly ...
Shaji Kumar, MD, a myeloma specialist from Mayo Clinic in Rochester, Minnesota, reviews recent updates in late-phase ...
According to findings presented at the 2021 ASH Annual Meeting, the combination of daratumumab, carfilzomib, ...
Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 ...
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
Shaji Kumar, MD, a myeloma specialist from Mayo Clinic in Rochester, Minnesota, discusses the upcoming changes in the ...
The combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell ...
In a phase I trial, the B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...
A recent study, led by Gabriel Tremblay, analyzed data from STORM—a phase IIb clinical trial on selinexor and low dose ...
A phase III clinical trial compared treatment with daratumumab, dexamethasone, and lenalidomide against dexamethasone ...
A meta-analysis, conducted by Wu Ye and collaborators from the Department of Hematology at the West China Hospital, ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.